PMID- 19712993
OWN - NLM
STAT- MEDLINE
DCOM- 20100921
LR  - 20220330
IS  - 1872-8332 (Electronic)
IS  - 0169-5002 (Linking)
VI  - 68
IP  - 3
DP  - 2010 Jun
TI  - Protein overexpression and gene amplification of epidermal growth factor receptor 
      in nonsmall cell lung carcinomas: Comparison of four commercially available 
      antibodies by immunohistochemistry and fluorescence in situ hybridization study.
PG  - 375-82
LID - 10.1016/j.lungcan.2009.07.014 [doi]
AB  - Epidermal growth factor receptor (EGFR) overexpression in nonsmall cell lung 
      carcinomas (NSCLC) is variable ranging from 19% to 89% and its prognostic value 
      remains controversial. We tried to investigate (1) EGFR protein expression using 
      four different antibodies, (2) the correlation between protein overexpression and 
      EGFR gene amplification, and (3) the correlation between EGFR genetic status and 
      clinicopathologic features in NSCLC. We examined EGFR protein expression using 
      four different antibodies including Zymed EGFR kit (Clone 31G7), Dako EGFR 
      pharmDx kit (Clone 2-18C9), Dako (Clone H11) and Novocastra (Clone EGFR 113) by 
      immunohistochemical analysis. The protein overexpression was compared to gene 
      amplification status by fluorescence in situ hybridization (FISH). EGFR protein 
      overexpression was observed in 56% of tumors with Zymed EGFR kit, in 51% with 
      Dako EGFR pharmDx kit, in 5% with Dako and in 18% with Novocastra (p=0.010). Both 
      Zymed and Dako pharmDx kit were more sensitive than the Dako test (clone H11) and 
      Novocastra clone EGFR 113. EGFR overexpression was more prominent in squamous 
      cell carcinomas (SCC) than adenocarcinomas (ADC) (71% vs. 48%, p=0.001 with 
      Zymed, 61% vs. 45%, p=0.011 with Dako pharmDx kit; respectively). EGFR 
      FISH-positivity as represented by high polysomy and gene amplification was 
      observed in 45% of the NSCLC patients. Protein expression levels significantly 
      correlated with the gene copy number per tumor cell (p<0.001). Our data showed a 
      higher percentage of positive cells detected by Zymed and Dako pharmDx tests. The 
      EGFR protein overexpression rate varied from 4% to 72% according to different 
      antibody clones and histologic types. EGFR protein expression detected by Zymed 
      and Dako pharmDx was significantly associated with a high EGFR gene copy number.
CI  - Copyright 2009 Elsevier Ireland Ltd. All rights reserved.
FAU - Lee, Hyun Ju
AU  - Lee HJ
AD  - Department of Pathology, Seoul National University College of Medicine, 28 
      Yongon-dong, Chongno-gu, Seoul 110-799, Republic of Korea.
FAU - Xu, Xianhua
AU  - Xu X
FAU - Choe, Gheeyoung
AU  - Choe G
FAU - Chung, Doo Hyun
AU  - Chung DH
FAU - Seo, Jeong-Wook
AU  - Seo JW
FAU - Lee, Jae Ho
AU  - Lee JH
FAU - Lee, Choon-Taek
AU  - Lee CT
FAU - Jheon, Sanghoon
AU  - Jheon S
FAU - Sung, Sook-Whan
AU  - Sung SW
FAU - Chung, Jin-Haeng
AU  - Chung JH
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20090826
PL  - Ireland
TA  - Lung Cancer
JT  - Lung cancer (Amsterdam, Netherlands)
JID - 8800805
RN  - 0 (Antibodies)
RN  - 0 (Reagent Kits, Diagnostic)
RN  - EC 2.7.10.1 (ErbB Receptors)
SB  - IM
MH  - Antibodies
MH  - Carcinoma, Non-Small-Cell 
      Lung/*diagnosis/genetics/*metabolism/pathology/physiopathology
MH  - Commerce
MH  - ErbB Receptors/genetics/immunology/*metabolism
MH  - Gene Amplification/genetics
MH  - Humans
MH  - *Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Lung Neoplasms/*diagnosis/genetics/*metabolism/pathology/physiopathology
MH  - Prognosis
MH  - *Reagent Kits, Diagnostic
MH  - Sensitivity and Specificity
EDAT- 2009/08/29 09:00
MHDA- 2010/09/23 06:00
CRDT- 2009/08/29 09:00
PHST- 2009/04/01 00:00 [received]
PHST- 2009/06/11 00:00 [revised]
PHST- 2009/07/23 00:00 [accepted]
PHST- 2009/08/29 09:00 [entrez]
PHST- 2009/08/29 09:00 [pubmed]
PHST- 2010/09/23 06:00 [medline]
AID - S0169-5002(09)00427-9 [pii]
AID - 10.1016/j.lungcan.2009.07.014 [doi]
PST - ppublish
SO  - Lung Cancer. 2010 Jun;68(3):375-82. doi: 10.1016/j.lungcan.2009.07.014. Epub 2009 
      Aug 26.